» Articles » PMID: 22876741

Safety Monitoring of Herb-drug Interactions: a Component of Pharmacovigilance

Overview
Journal Drug Saf
Specialties Pharmacology
Toxicology
Date 2012 Aug 11
PMID 22876741
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Adverse drug reactions, including those resulting from interactions between herbal medicines and conventional drugs, are a public health problem worldwide. The need for pharmacovigilance for herb-drug interactions (HDIs) is essential for the identification and assessment of risks of using herbal products (questionable safety, efficacy and quality), which are not always tested with rigor, or often not subject to approval by regulatory agencies. Spontaneous and active surveillance conducted by national pharmacovigilance centres permits a rapid detection of potentially harmful combinations of products. The incidence and prevalence of HDIs are difficult to predict because of the underreporting of adverse effects. It is important for health professionals, consumers, regulatory authorities and suppliers of herbal medicines to be aware of the possible adverse effects and drug interactions caused when herbal medicines are co-administered with conventional drugs. National pharmacovigilance centres continue to play a significant role in increasing awareness of drug safety, in this case with HDIs. The authors' objective for this paper is to provide awareness among policy makers responsible for the design of appropriate pharmacovigilance practices and therefore to highlight the importance of pharmacovigilance in the safety monitoring of HDIs.

Citing Articles

Estimating Adverse Events Associated With Herbal Medicines Using Pharmacovigilance Databases: Systematic Review and Meta-Analysis.

Kongkaew C, Phan D, Janusorn P, Mongkhon P JMIR Public Health Surveill. 2024; 10:e63808.

PMID: 39208414 PMC: 11393504. DOI: 10.2196/63808.


Safety Aspects of Herb Interactions: Current Understanding and Future Prospects.

Hazra S, Singh P Curr Drug Metab. 2024; 25(1):28-53.

PMID: 38482621 DOI: 10.2174/0113892002289753240305062601.


Suspected cutaneous adverse drug reactions reported with traditional medicines: analysis of data for United Nations Asia region from WHO VigiBase.

Barvaliya M, Chetan A, Chandan N, Ray S, Hegde H, Unger B Front Pharmacol. 2023; 14:1088841.

PMID: 37324461 PMC: 10261983. DOI: 10.3389/fphar.2023.1088841.


The Safety of Herbal Medicines (Phytovigilance) from Community Pharmacists' Perspective: A Cross-Sectional Study.

Memisoglu M, Otlatici G Turk J Pharm Sci. 2022; 19(3):280-286.

PMID: 35775245 PMC: 9254090. DOI: 10.4274/tjps.galenos.2021.77178.


Analysis of Hepatobiliary Disorder Reports Associated With the Use of Herbal Medicines in the Global Suspected ADR Database Vigibase.

van Hunsel F, van de Koppel S, Skalli S, Kuemmerle A, Teng L, Wang J Front Pharmacol. 2019; 10:1326.

PMID: 31780942 PMC: 6851844. DOI: 10.3389/fphar.2019.01326.


References
1.
McCabe B . Prevention of food-drug interactions with special emphasis on older adults. Curr Opin Clin Nutr Metab Care. 2004; 7(1):21-6. DOI: 10.1097/00075197-200401000-00005. View

2.
Skalli S, Zaid A, Soulaymani R . Drug interactions with herbal medicines. Ther Drug Monit. 2007; 29(6):679-86. DOI: 10.1097/FTD.0b013e31815c17f6. View

3.
Delgoda R, Younger N, Barrett C, Braithwaite J, Davis D . The prevalence of herbs use in conjunction with conventional medicines in Jamaica. Complement Ther Med. 2010; 18(1):13-20. DOI: 10.1016/j.ctim.2010.01.002. View

4.
Hennessy M, Kelleher D, Spiers J, Barry M, Kavanagh P, Back D . St Johns wort increases expression of P-glycoprotein: implications for drug interactions. Br J Clin Pharmacol. 2002; 53(1):75-82. PMC: 1874544. DOI: 10.1046/j.0306-5251.2001.01516.x. View

5.
Zhou W, Chai H, Lin P, Lumsden A, Yao Q, Chen C . Molecular mechanisms and clinical applications of ginseng root for cardiovascular disease. Med Sci Monit. 2004; 10(8):RA187-92. View